National Medical Care Company (4005) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
23 Feb, 2026Executive summary
Achieved 24% year-on-year revenue growth to SAR 1.6 billion in FY 2025, driven by higher patient volumes and the full-year impact of Al Salam Hospital.
Patient volumes rose 33% to 985,088, with outpatient visits up 32% and inpatient admissions up 39%.
Net profit increased 8% to SAR 318 million, with underlying net profit up 43% year-on-year after adjusting for one-off reversals.
Strategic expansion included full-year contribution from Al Salam Hospital, ongoing M&A, and a focus on digital innovation and operational excellence.
Strategy refresh targets geographic expansion, operational efficiency, and digital transformation.
Financial highlights
Gross profit increased 31% to SAR 589 million, with gross margin up 1.9 percentage points to 36.8%.
EBITDA grew 23% to SAR 465 million, maintaining a margin of 29.1%.
Net profit margin declined to 19.9% due to absence of prior year one-off reversals.
Revenue growth was broad-based, with Rawabi and Malaz branches contributing 45% and 39% of total revenue, respectively.
Operating expenses rose 49% year-on-year, mainly due to SG&A and professional fees.
Outlook and guidance
Plans to add 5–8 new facilities by 2032, including the 400-bed Al Narjis Hospital in Riyadh.
Focus on automation, digital health, and operational efficiency to sustain growth and margins.
Margin improvement targeted via operational efficiencies and contract renegotiations, especially at Al Salam.
Aim to maintain or improve margins until Al Narjis opens, barring major M&A.
Continued investment in talent and a patient-centric model to drive sustainable growth.
Latest events from National Medical Care Company
- Record Q2 2026 profit and margin recovery driven by GOSI and patient volume growth.4005
Q2 2026 - Stable revenue and strong patient growth offset by lower margins and profit amid seasonal headwinds.4005
Q1 2026 - 30% revenue and 17% net profit growth in 9M 2025, driven by expansion and integration.4005
Q3 2025 - Revenue up 32% and net profit up 10% in 1H 2025, fueled by patient and facility growth.4005
Q2 2025 - Net profit up 45% to SAR 151m on 18% revenue growth, with margin and capacity gains.4005
Q2 2024 - Net profit up 19% and revenue up 18% in 9M 2024, driven by expansion and acquisitions.4005
Q3 2024 - Revenue up 29% and EBITDA up 38% in 1Q 2025, driven by patient and service growth.4005
Q1 2025 - Net profit up 24% to SAR 298mn, with 20% revenue growth and improved margins.4005
Q4 2024